



Pharmacokinetics and Pharmacodynamics of Psychoactive Substances: Clinical and Forensic Aspects 2023

Guest Editor:

Message from the Guest Editor

Prof. Dr. Ricardo Jorge Dinis-Oliveira

1. Associate Laboratory i4HB—Institute for Health and Bioeconomy, University Institute of Health Sciences—IUCS-CESPU, 4585-116 Gandra, Portugal

2. UCIBIO—Research Unit on Applied Molecular Biosciences, Translational Toxicology Research Laboratory, University Institute of Health Sciences (IH-TOXRUN, IUCS-CESPU), 4585-116 Gandra, Portugal

3. Department of Public Health and Forensic Sciences and Medical Education, Faculty of Medicine, University of Porto, 4200-319 Porto, Portugal

4. FOREN—Forensic Science Experts, Dr. Mário Moutinho Avenue, No. 33-A, 1400-136 Lisbon, Portugal

Dear Colleagues,

This Special Issue aims to cover the chemical structure, available products, pharmacokinetics, pharmacodynamics, metabolomics, clinical manifestations, diagnostics, and treatment of acute intoxications related to psychoactive substances in order to highlight their impact on public health. To better understand the clinical and forensic effects, pharmacokinetics should be explored to find active and inactive metabolites and other biomarkers. Indeed, polymorphisms in genes encoding enzymes (e.g., CYP2B6) involved in metabolism or target receptors may influence both drug efficacy and toxicity. Besides genetics, the extensive metabolism by P450 can lead to important interactions when drugs are taken concomitantly. The identification of additional metabolites is also needed during drug development and for clinical and forensic toxicology, where specific metabolites are used to confirm xenobiotic exposure as potential biomarkers.

Deadline for manuscript submissions:

closed (31 May 2024)





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e
Bioquímica (DQB) e Centro de
Química Estrutural (CQE),
Institute of Molecular Sciences,
Faculdade de Ciências,
Universidade de Lisboa, Lisboa,
Portugal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*.

Pharmaceuticals is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [Embase](#), [CAPus / SciFinder](#), and [other databases](#).

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

Contact Us

Pharmaceuticals Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/pharmaceuticals
pharmaceuticals@mdpi.com
[X@Pharmaceut_MDPI](https://twitter.com/Pharmaceut_MDPI)